Impax Laboratories' generic version of GlaxoSmithKline's heart failure drug Coreg CR, or carvedilol phosphate, was granted tentative FDA approval. Impax's marketing application is eligible for FDA final approval upon expiration of GSK's patent protection on May 7, 2018.
Luke Miels, the new head of pharmaceuticals at GlaxoSmithKline, said the company will focus on buying or licensing early-stage cancer and immunology drugs. After gaining recent approvals for three new products -- for shingles, HIV and chronic obstructive pulmonary disease -- the company will not launch others until after 2020.
The medical device industry has expressed frustration about Congress' inaction to repeal the medical device tax despite lawmakers saying "the right thing" during their meetings, said AdvaMed President and CEO Scott Whitaker after the House and the Senate failed to include the tax when they resolved plans on tax cuts. Whitaker said he believes a last-minute plan would be devised by Congress to prevent the tax from being implemented and said the industry group will go to congressional districts to talk about the tax's impact if the issue bleeds into 2018.
A study in Hemodialysis International found the use of NxStage Medical's Nx2me Connected Health remote patient management system in-home hemodialysis demonstrated a 29% reduction in technique failure or conversion to in-center hemodialysis. The findings, based on data from 606 patients, showed use of the system within three months after initiation of home hemodialysis was associated with a 34% reduction in technique failure.
A magistrate judge recommended the US District Court for the District of Delaware dismiss Amgen's patent infringement lawsuit against Coherus Biosciences. Amgen filed the suit after Coherus' submission of a marketing application for a biosimilar of Neulasta, or pegfilgrastim.
The FDA approved the pathway to resubmission of SteadyMed's new-drug application for Trevyent, which requires that SteadyMed only repeat the in vitro design verification testing on the final product. The company anticipates the filing and acceptance of the drug before the end of next year.
The National Institute for Health and Care Excellence recommended the use of Novartis' Zykadia, or ceritinib, as a treatment for adult patients with untreated ALK-positive non-small cell lung cancer at a confidential discounted price agreed upon with the company. The institute also recommended the use of Maviret, or glecaprevir-pibrentasvir, in adult patients with chronic hepatitis C.
The FDA issued warning letters to seafood and juice importer Bedessee Imports, dairy Hilgenkamp Farm and airline caterer Tufo's To Go over violations of federal food safety rules. The agency observed multiple violations among the companies, including violations on Seafood Hazard Analysis and Critical Control Point regulation, the Juice Hazard Analysis and Critical Control Point regulation and the Current Good Manufacturing Practice regulation for foods.
Kyowa Hakko Kirin's Poteligeo, or mogamulizumab, achieved the primary endpoint of a late-stage study, in which it led to a median progression-free survival of 7.7 months compared with 3.1 months for Zolinza, or vorinostat, in patients with Sezary syndrome.
- Page 1